Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : DNAG - DNAPrint Genomics -- Ignore unavailable to you. Want to Upgrade?

To: Olav who wrote (241)	2/21/2003 7:22:22 PM
From: Theo	Respond to of 409

Press Release Source: DNAPrint genomics, Inc. DNAPrint Presents at 55th Annual AAFS Meeting Friday February 21, 12:58 pm ET SARASOTA, Fla., Feb. 21 /PRNewswire-FirstCall/ -- DNAPrint (OTC Bulletin Board: DNAP - News; the "Company"), the world leader in the measurement of population structure for disease genetics, personalized medicine, forensics profiling and consumer genomics, has presented at the 55th Annual Meeting for the American Association of Forensic Scientists. Zach Gaskin presented the Company's DNAWitness suite of physical profiling products to the world's leading forensics laboratory directors and scientists. Several hundred CD-ROMs detailing validation and challenges to the suite were distributed. The focus was on the Company's Ancestry 2.0 test, which is a forensics version of the company's successful recreational product, AncestrybyDNA 2.0. Both tests measure Ancestry Informative Markers (AIMs) across the genome in order to determine the proportionality of biogeographical ancestry (BGA) within individuals. The measurement of BGA admixture proportions is useful for forensic scientists who desire to reconstruct a partial physical profile from crime scene DNA. The AAFS meeting is being held February 17-22, 2003, in Chicago, IL. The response to the presentation was overwhelming and during the first two days of the conference, DNAPrint's booth was one of the most popular at the show. To learn more about the AAFS please visit aafs.org . About DNAPrint genomics, Inc. DNAPrint genomics Inc. was founded by a team of scientists with research and commercial experience in high-level mathematical modeling, programming and molecular genetics. Using proprietary human genome research methods, the Company develops chemopredictive tests for matching patients with drugs based on their genetic constitution, discovers disease genes for the development of new drugs and develops new forensic genomics and recreational genomics testing products. The Company is traded on the Nasdaq OTC Bulletin Board under the ticker symbol: DNAP. For more information about the company, please visit www.dnaprint.com. All statements in this press release that are not historical are forward- looking statements within the meaning of Section 21E of the Securities Exchange Act as amended. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint genomics, Inc. expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based. Media and Press Contacts Phil Brooks DNAPrint genomics, Inc. Director, Marketing (941) 366-3400 pbrooks@ancestrybydna.com